Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | EEF2K | O00418 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155595 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPTL3MBTL1CYP26A1 | |
| SCHEMBL16680856 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPTL3MBTL1CYP26A1 | |
| SCHEMBL6359617 | 0.87 | RIPK1 (0.50) | L3MBTL1PTPRCCTSSCTSKRIPK1 | |
| SCHEMBL6359621 | 0.87 | RIPK1 (0.50) | L3MBTL1PTPRCCTSSCTSKRIPK1 | |
| SCHEMBL6936747 | 0.86 | MEN1 (0.41) | ALDH1A1SMN1; SMN2PTPRCCTSSCTSK | |
| SCHEMBL24326335 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPTL3MBTL1PTPRCCTSS | |
| SCHEMBL17697851 | 0.84 | EEF2K (0.46) | ALDH1A1SMN1; SMN2MAPTL3MBTL1EEF2K | |
| SCHEMBL3547381 | 0.82 | TDP1 (0.48) | ALDH1A1L3MBTL1PTPRCCTSSCTSK | |
| SCHEMBL19193984 | 0.81 | L3MBTL1 (0.54) | L3MBTL1PTPRCCTSSCTSK | |
| SCHEMBL27551142 | 0.81 | L3MBTL1 (0.54) | L3MBTL1PTPRCCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| EP-1501795-B1 | CINNAMIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060178369-A1 | Cinnamic acid amides | INTERMED DISCOVERY GMBH (DE) | 2006-08-10 | — | — | US | disclosed |
| EP-1501795-A1 | CINNAMIC ACID AMIDES | Bayer Aktiengesellschaft (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091212-A1 | CINNAMIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178369-A1 | Cinnamic acid amides | PIGS, NISCH, PIGO | ALDH1A1 262/4885SMN1; SMN2 2623/4885MAPT 2050/4885 |
| US-20090149528-A1 | Cinnamic acid amides | PIGS, NISCH, PIGO | ALDH1A1 262/4885SMN1; SMN2 2623/4885MAPT 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.